A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells

Human epithelial growth factor receptor-2 (HER2) plays an oncogenic role in numerous tumors, including breast, gastric, and various other solid tumors. While anti-HER2 therapies are approved for the treatment of HER2-positive tumors, a necessity persists for creating novel HER2-targeted agents to re...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xinlin, Luan, Linli, Liu, Xi, Jiang, Dingwen, Deng, Junwen, Xu, Jiazhen, Yuan, Yang, Xing, Jiyao, Chen, Bingguan, Xing, Dongming, Huang, Haiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634241/
https://www.ncbi.nlm.nih.gov/pubmed/37954614
http://dx.doi.org/10.3389/fimmu.2023.1292839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634241/
https://www.ncbi.nlm.nih.gov/pubmed/37954614
http://dx.doi.org/10.3389/fimmu.2023.1292839

Ejemplares similares